Prothena (PRTA) Raised to Sell at BidaskClub

Prothena (NASDAQ:PRTA) was upgraded by analysts at BidaskClub from a “strong sell” rating to a “sell” rating in a research report issued to clients and investors on Thursday.

PRTA has been the topic of a number of other research reports. Oppenheimer set a $70.00 target price on Prothena and gave the company a “buy” rating in a research report on Monday, December 4th. Deutsche Bank set a $73.00 target price on Prothena and gave the company a “buy” rating in a research report on Monday, October 23rd. Cantor Fitzgerald reissued a “buy” rating and issued a $65.00 target price on shares of Prothena in a research report on Wednesday, December 20th. ValuEngine lowered Prothena from a “hold” rating to a “sell” rating in a research report on Friday, October 6th. Finally, Wedbush lowered Prothena from an “outperform” rating to a “neutral” rating and cut their target price for the company from $75.00 to $55.00 in a research report on Monday, November 20th. Three equities research analysts have rated the stock with a sell rating, one has given a hold rating and eleven have assigned a buy rating to the company’s stock. The company has a consensus rating of “Buy” and a consensus price target of $75.58.

Shares of Prothena (NASDAQ PRTA) traded up $1.36 during midday trading on Thursday, reaching $39.62. The company’s stock had a trading volume of 372,800 shares, compared to its average volume of 312,555. The stock has a market capitalization of $1,500.00, a price-to-earnings ratio of -9.34 and a beta of 2.43. Prothena has a 52 week low of $34.85 and a 52 week high of $70.00.

Prothena (NASDAQ:PRTA) last announced its earnings results on Tuesday, November 7th. The biotechnology company reported ($1.37) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($1.41) by $0.04. The company had revenue of $0.19 million for the quarter, compared to analyst estimates of $0.28 million. Prothena had a negative return on equity of 34.40% and a negative net margin of 562.19%. The firm’s quarterly revenue was down 33.6% compared to the same quarter last year. During the same quarter in the previous year, the company earned ($1.26) earnings per share. equities research analysts predict that Prothena will post -4.27 EPS for the current fiscal year.

Large investors have recently bought and sold shares of the business. Quantbot Technologies LP grew its stake in shares of Prothena by 672.7% in the second quarter. Quantbot Technologies LP now owns 1,870 shares of the biotechnology company’s stock worth $101,000 after acquiring an additional 1,628 shares in the last quarter. Zurcher Kantonalbank Zurich Cantonalbank grew its stake in shares of Prothena by 187.5% in the second quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 2,375 shares of the biotechnology company’s stock worth $129,000 after acquiring an additional 1,549 shares in the last quarter. Strs Ohio grew its stake in shares of Prothena by 69.2% in the third quarter. Strs Ohio now owns 2,200 shares of the biotechnology company’s stock worth $142,000 after acquiring an additional 900 shares in the last quarter. Fieldpoint Private Securities LLC acquired a new position in shares of Prothena in the third quarter worth $162,000. Finally, Ameritas Investment Partners Inc. grew its stake in shares of Prothena by 8.3% in the second quarter. Ameritas Investment Partners Inc. now owns 3,249 shares of the biotechnology company’s stock worth $176,000 after acquiring an additional 250 shares in the last quarter.

COPYRIGHT VIOLATION NOTICE: This story was reported by Markets Daily and is owned by of Markets Daily. If you are accessing this story on another domain, it was illegally stolen and republished in violation of international trademark & copyright legislation. The original version of this story can be viewed at https://www.themarketsdaily.com/2018/01/12/prothena-prta-raised-to-sell-at-bidaskclub.html.

Prothena Company Profile

Prothena Corporation Public Limited Company is a global biotechnology company. The Company is focused on the discovery, development and commercialization of immunotherapies for the treatment of diseases that involve protein misfolding or cell adhesion. The Company’s clinical pipeline of antibody-based product candidates targets a range of indications, including Amyloid Light-chain (AL) amyloidosis (NEOD001), Parkinson’s disease and other related synucleinopathies (PRX002), and inflammatory diseases, including psoriasis and psoriatic arthritis (PRX003) and ATTR amyloidosis (PRX004).

Analyst Recommendations for Prothena (NASDAQ:PRTA)

Receive News & Ratings for Prothena Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Prothena and related companies with MarketBeat.com's FREE daily email newsletter.

Latest News

Leave a Reply